Lake Street Maintains Buy on AVITA Medical, Raises Price Target to $20
Benzinga Newsdesk 23 hours ago
Analyst RatingsNewsPrice Target
Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $20.
Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $20.